Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.40 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1622071 | 0.94 | ALDH1A1 (0.50) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL1533859 | 0.86 | ALDH1A1 (0.44) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL6259283 | 0.80 | TSHR (0.55) | ALDH1A1CA2TSHR | |
| SCHEMBL1156282 | 0.80 | ALDH1A1 (0.54) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL7979524 | 0.80 | ALDH1A1 (0.54) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL20190329 | 0.79 | ALDH1A1 (0.52) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL29271182 | 0.78 | LMNA (0.40) | CA2CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL1621128 | 0.78 | CA2 (0.53) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL6985786 | 0.78 | ALDH1A1 (0.52) | ALDH1A1CA2CHRM5CHRM1CHRM3 | |
| SCHEMBL6985783 | 0.78 | ALDH1A1 (0.52) | ALDH1A1CA2CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-112424201-B | Protein kinase inhibitors that promote liver regeneration or reduce or prevent hepatocyte death | 海帕瑞吉尼克斯股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| CN-116854681-A | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-110177783-B | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001098282-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2001-12-27 | — | — | WO | disclosed |
| EP-0562439-B1 | Triazolopyridazines as antioasthmatics | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0562440-B1 | Imidazopyridazines as antiasthmatics | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5491145-A | ANTIASTHMA, ANTI-PLATELET ACTIVATING FACTOR BRONCHOCONSTRICTION-INHIBITING AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-13 | — | — | US | disclosed |
| US-5482939-A | ANTI-PLATELET ACTIVATING FACTOR ACTIVITIES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-09 | — | — | US | disclosed |
| US-5389633-A | ANTIASTHMATIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0562439-A1 | Triazolopyridazines as antioasthmatics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0562440-A1 | Imidazopyridazines as antiasthmatics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-4315014-A | Antibacterial amide compounds and pharmaceutical composition containing the same | WARNER-LAMBERT COMPANY (US) | 1982-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAPK7, MAPK14 | ALDH1A1 4181/4885CA2 4003/4885CHRM5 4082/4885 |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | ALDH1A1 2057/4885CA2 3287/4885CHRM5 1093/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | ALDH1A1 2057/4885CA2 3287/4885CHRM5 1093/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | ALDH1A1 2833/4885CA2 4045/4885CHRM5 4768/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | ALDH1A1 2777/4885CA2 3749/4885CHRM5 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.